[HTML][HTML] Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor …
T De Pas, F Toffalorio, M Manzotti, C Fumagalli… - Journal of Thoracic …, 2011 - Elsevier
Introduction Mutations of the epidermal growth factor receptor (EGFR) have been proven to
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
predict activity of the EGFR-tyrosine kinase inhibitors (EGFR-TKI), gefitinib and erlotinib …
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …
PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small cell lung cancer
Purpose: Clinical features of epidermal growth factor receptor (EGFR) mutations, L858R,
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
deletions in exon 19, T790M, and insertions in exon 20, in non–small cell lung cancer …
[HTML][HTML] Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung …
S Murray, IJ Dahabreh, H Linardou… - Journal of thoracic …, 2008 - Elsevier
Background After the discovery of somatic mutations in the tyrosine kinase domain (exons
18–24) of the epidermal growth factor receptor (EGFR) correlating with responses of non …
18–24) of the epidermal growth factor receptor (EGFR) correlating with responses of non …
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
K Chen, X Yu, H Wang, Z Huang, Y Xu, L Gong… - Cancer Chemotherapy …, 2017 - Springer
Purpose Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
standard therapy for advanced lung adenocarcinomas with common EGFR mutations …
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and …
E Massarelli, FM Johnson, HS Erickson, II Wistuba… - Lung Cancer, 2013 - Elsevier
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
dramatic tumor responses and favorable clinical outcomes in a select group of non-small …
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations
L Peng, ZG Song, SC Jiao - Scientific reports, 2014 - nature.com
The efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) in
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
patients with non-small cell lung cancer (NSCLC) is related to EGFR mutations. Although the …
[HTML][HTML] Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors
S Kobayashi, HM Canepa, AS Bailey… - Journal of Thoracic …, 2013 - Elsevier
Background: Non–small-cell lung cancers (NSCLCs) containing EGFR mutations are
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
exquisitely sensitive to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors …
Effectiveness of tyrosine kinase inhibitors in Japanese patients with non-small cell lung cancer harboring minor epidermal growth factor receptor mutations: results …
T Otsuka, M Mori, Y Yano, J Uchida… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: Non-small cell lung cancer (NSCLC) with minor mutations in the epidermal growth
factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and …
factor receptor (EGFR) gene, except for the common 15 base-pair deletions in exon 19 and …